A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

被引：0
|
作者：
Ross, Robert W. [1 ]
Srinivasan, Ramaprasad [2 ]
Vaishampayan, Ulka [3 ]
Bukowski, Ronald [4 ]
Rosenberg, Jonathan [5 ]
Eisenberg, Peter [6 ]
Logan, Theodore [7 ]
Srinivas, Sandhya [8 ]
Stein, Mark [9 ]
Mueller, Thomas [10 ]
Keer, Harold N. [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Natl Canc Inst, Urol Oncol Branch, Bethesda, MD USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Cleveland Clin, Cleveland, OH USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] California Canc Ctr, Greenbrae, CA USA
[7] Indiana Univ, Ctr Canc, Indianapolis, IN USA
[8] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA
[9] Inst Canc Res, New Brunswick, NJ USA
[10] Exelixis Inc, San Francisco, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3511S / 3511S
页数：1
相关论文
共 50 条
  • [21] A phase 1 study of a novel spectrum selective inhibitor (SSKI), XL880, administered orally in patients with advanced solid malignancies.
    LoRusso, P
    Appleman, L
    Heath, E
    Malburg, L
    Zhu, AX
    Carey, M
    Shapiro, GI
    Eder, JP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [22] Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
    Yakes, F. Michael
    Chen, Jason
    Tan, Jenny
    Yamaguchi, Kyoko
    Shi, Yongchang
    Yu, Peiwen
    Qian, Fawn
    Chu, Felix
    Bentzien, Frauke
    Cancilla, Belinda
    Orf, Jessica
    You, Andrew
    Laird, A. Douglas
    Engst, Stefan
    Lee, Lillian
    Lesch, Justin
    Chou, Yu-Chien
    Joly, Alison H.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2298 - 2308
  • [23] Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
    Hsu, Jeff
    Chong, Colin
    Serrill, Jeffrey
    Goon, Levina
    Balayan, Joan
    Johnson, Eric N.
    Lorenzana, Grachelle
    Wu, Sharon
    Leong, Kevin G.
    Yun, Theodore J.
    Wang, Yong
    Jiang, Faming
    Bannen, Lynne
    Lamb, Peter
    Xu, Wei
    Yu, Peiwen
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (02) : 179 - 191
  • [24] XL092, amulti-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile
    Hsu, J.
    Chong, C.
    Goon, L.
    Balayan, J.
    Wu, S.
    Johnson, E.
    Lorenzana, G.
    Bannen, L.
    Nguyen, L.
    Scheffold, C.
    Lamb, P.
    Xu, W.
    Yu, P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S16 - S16
  • [25] Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET
    Muller, Thomas
    DePrimo, Samuel
    McGrath, Garth
    Yu, Peiwen
    Wu, Jianming
    Goon, Levina
    Lee, Michelle
    de Costa, Anushka
    Chu, Felix
    Cancilla, Belinda
    Huang, Stephen
    Vysotskaia, Valentina
    Li, Jonathan
    Zhao, Lora
    Wong, Mei
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [26] In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
    Bentzien, Frauke
    Zuzow, Marcus
    Heald, Nathan
    Gibson, Anna
    Shi, Yongchang
    Goon, Leanne
    Yu, Peiwen
    Engst, Stefan
    Zhang, Wentao
    Huang, Donghui
    Zhao, Lora
    Vysotskaia, Valentina
    Chu, Felix
    Bautista, Rajana
    Cancilla, Belinda
    Lamb, Peter
    Joly, Alison H.
    Yakes, F. Michael
    THYROID, 2013, 23 (12) : 1569 - 1577
  • [27] The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
    Yu Zhang
    Xiaomei Gao
    Ying Zhu
    Dhruba Kadel
    Haoran Sun
    Jing Chen
    Qin Luo
    Haoting Sun
    Luyu Yang
    Jing Yang
    Yuanyuan Sheng
    Yan Zheng
    Kejin Zhu
    Qiongzhu Dong
    Lunxiu Qin
    Journal of Experimental & Clinical Cancer Research, 37
  • [28] The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
    Zhang, Yu
    Gao, Xiaomei
    Zhu, Ying
    Kadel, Dhruba
    Sun, Haoran
    Chen, Jing
    Luo, Qin
    Sun, Haoting
    Yang, Luyu
    Yang, Jing
    Sheng, Yuanyuan
    Zheng, Yan
    Zhu, Kejin
    Dong, Qiongzhu
    Qin, Lunxiu
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [29] The dual c-Met/VEGFR2 inhibitor foretinib augments chemotherapy response in preclinical models of gastric cancer
    Awasthi, Niranjan
    Grojean, Meghan
    Monahan, Sheena
    Hassan, Sazzad
    von Holzen, Urs
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER RESEARCH, 2018, 78 (13)
  • [30] A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies
    Salgia, R.
    Hong, D. S.
    Camacho, L. H.
    Ng, C. S.
    Janisch, L.
    Ratain, M. J.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345